LCCC 0509: A TWO-ARM PHASE I DOSE ESCALATION TRIAL OF VINFLUNINE

LCCC 0509：Vinflunine 的双臂 I 期剂量递增试验

• 批准号: 7625662
• 负责人: ELIZABETH CLAIRE DEES
• 金额: $ 1.07万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7625662
• 关键词: CYP3A4 gene; Computer Retrieval of Information on Scientific Projects Database; Dose; Enrollment; Erlotinib; Funding; Grant; Institution; Label; Maximum Tolerated Dose; Midazolam; Patients; Pemetrexed; Phase; Randomized; Refractory; Research; Research Personnel; Resources; Solid Neoplasm; Source; United States National Institutes of Health; Upper arm; vinflunine

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is an open label, non-randomized phase I dose escalation trial in refractory solid tumors. Patients will be enrolled to one of two arms, vinflunine/erlotinib or vinflunine/pemetrexed, to define the maximum tolerated doses (MTD) of each combination. We will also investigate whether vinflunine is a CYP3A4 substrate, and if CYP3A4 activity predicts vinflunine clearance with the use of a midazolam CYP3A4 probe.

这个子项目是众多研究子项目之一